Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | BPX-601 |
Synonyms | |
Therapy Description |
BPX-601 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting human prostate stem cell antigen (PSCA) and the zeta chain of the T-cell receptor (TCRzeta), and a rimiducid-induced co-stimulatory molecule, which activates anti-tumor immune response (PMID: 27824842). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
BPX-601 | GoCART BPX-601|iMC/PSCA-zeta BPX 601|Autologous PSCA CAR T Cells BPX-601 | BPX-601 are autologous T lymphocytes engineered to express a chimeric antigen receptor (CAR) targeting human prostate stem cell antigen (PSCA) and the zeta chain of the T-cell receptor (TCRzeta), and a rimiducid-induced co-stimulatory molecule, which activates anti-tumor immune response (PMID: 27824842). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02477878 | Phase I | BPX-601 Rimiducid | Study of Gene Modified Donor T Cell Infusion in Patients With Recurrent Disease After Allogeneic Transplant | Active, not recruiting | USA | 0 |